---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-057911"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:38:37.026198+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Atea reports Q4 net income of $117.1M on Roche revenue recognition; pivots COVID-19 pipeline to combo

## Summary
- Full year 2021 net income $121.2M vs net loss $10.9M in 2020; revenue of $351.4M from Roche license termination.
- Phase 3 MORNINGSKY trial closed; COVID-19 program shifts to Phase 2 combination with a protease inhibitor in 2H 2022.
- Initiated Phase 2 HCV combination trial of bemnifosbuvir and ruzasvir (in-licensed from Merck) in 2H 2022.
- AT-752 Phase 2 dengue program expected to start 1H 2022 with results late 2022; cash $764.4M at Dec 31, 2021.
- Roche collaboration terminated effective Feb 10, 2022; Atea regains full worldwide rights to bemnifosbuvir.

## SEC filing metadata
- accession: 0001193125-22-057911
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312522057911/0001193125-22-057911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312522057911/d279167d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-057911
- JSON: https://secwatch.observer/filing/0001193125-22-057911.json
- Plain text: https://secwatch.observer/filing/0001193125-22-057911.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.